New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
12:01 EDTAEZSAeterna Zentaris NDA filing for macimorelin acetate accepted by FDA
Aeterna Zentaris announced that the Food and Drug Administration has accepted for filing the company's New Drug Application for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency. The company's NDA, submitted on November 5, 2013, seeks approval for the commercialization of macimorelin acetate as the first orally-administered product that induces growth hormone release to evaluate AGHD. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review, the company said.
News For AEZS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2014
07:33 EDTAEZSAeterna Zentaris appoints Philip Theodore as Chief Administrative Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use